Compare JBI & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | BLFS |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.3M | 1.2B |
| IPO Year | N/A | 1989 |
| Metric | JBI | BLFS |
|---|---|---|
| Price | $6.80 | $24.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $10.13 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 2.1M | 336.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $888,700,000.00 | $100,144,000.00 |
| Revenue This Year | N/A | $20.67 |
| Revenue Next Year | $1.58 | $14.13 |
| P/E Ratio | $20.28 | ★ N/A |
| Revenue Growth | N/A | ★ 87.53 |
| 52 Week Low | $5.73 | $19.10 |
| 52 Week High | $10.80 | $29.62 |
| Indicator | JBI | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 39.63 |
| Support Level | $5.96 | $24.44 |
| Resistance Level | $6.62 | $25.96 |
| Average True Range (ATR) | 0.28 | 0.87 |
| MACD | 0.21 | -0.08 |
| Stochastic Oscillator | 80.89 | 4.36 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.